Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; Solé, Montse; Monseny, Rosa; Franch, J.; Vilella, Elisabet; Labad, Javier

doi:10.1097/yic.0b013e32835ba832

Cited by 30 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Across all the studies, the proportion of subjects who experienced potentially prolactinrelated AEs (i.e. amenorrhea/gynecomastia/galactorrhoea) was below 4% for all dose groups (3mg, 6mg, 9mg and 12mg) [142].…”

Section: Adverse Effectsmentioning

confidence: 99%

An update of safety of clinically used atypical antipsychotics

Orsolini

Tomasetti

Valchera

et al. 2016

Expert Opinion on Drug Safety

117

View full text Add to dashboard Cite

A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.

show abstract

Section: Adverse Effectsmentioning

confidence: 99%

An update of safety of clinically used atypical antipsychotics

Orsolini

Tomasetti

Valchera

et al. 2016

Expert Opinion on Drug Safety

117

View full text Add to dashboard Cite

show abstract

“…As paliperidone is the major active metabolite of risperidone, the mechanism of PRL elevation for paliperidone is likely similar to that of risperidone [260–262]. However, two recently published studies suggest that PRL levels seem to decrease after switching from risperidone to paliperidone in patients with a psychotic disorder [263, 264]. An analysis of abnormal PRL values in ten randomized clinical trials, including 3,173 patients treated with paliperidone palmitate, showed that, overall, at any time, PRL levels were elevated for 38.8 % of the subjects [265].…”

Section: Prl and Antipsychoticsmentioning

confidence: 99%

The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review

et al. 2014

View full text Add to dashboard Cite

Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia (HPRL) as a common adverse effect of antipsychotic medication, which remains the cornerstone of pharmacological treatment for patients with schizophrenia. Although treatment with second-generation antipsychotics (SGAs) as a group is, compared with use of the first-generation antipsychotics, associated with lower prolactin (PRL) plasma levels, the detailed effects on plasma PRL levels for each of these compounds in reports often remain incomplete or inaccurate. Moreover, at this moment, no review has been published about the effect of the newly approved antipsychotics asenapine, iloperidone and lurasidone on PRL levels. The objective of this review is to describe PRL physiology; PRL measurement; diagnosis, causes, consequences and mechanisms of HPRL; incidence figures of (new-onset) HPRL with SGAs and newly approved antipsychotics in adolescent and adult patients; and revisit lingering questions regarding this hormone. A literature search, using the MEDLINE database (1966–December 2013), was conducted to identify relevant publications to report on the state of the art of HPRL and to summarize the available evidence with respect to the propensity of the SGAs and the newly approved antipsychotics to elevate PRL levels. Our review shows that although HPRL usually is defined as a sustained level of PRL above the laboratory upper limit of normal, limit values show some degree of variability in clinical reports, making the interpretation and comparison of data across studies difficult. Moreover, many reports do not provide much or any data detailing the measurement of PRL. Although the highest rates of HPRL are consistently reported in association with amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favorable profile with respect to this outcome, all SGAs can induce PRL elevations, especially at the beginning of treatment, and have the potential to cause new-onset HPRL. Considering the PRL-elevating propensity of the newly approved antipsychotics, evidence seems to indicate these agents have a PRL profile comparable to that of clozapine (asenapine and iloperidone), ziprasidone and olanzapine (lurasidone). PRL elevations with antipsychotic medication generally are dose dependant. However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Although tolerance and decreases in PRL values after long-term administration of PRL-elevating antipsychotics can occur, the elevations, in most cases, remain above the upper limit of normal. PRL profiles of antipsychotics in children and adolescents seem to be the same as in adults. The hyperprolactinemic effects of antipsychotic medication are mostly correlated with their affi...

show abstract

“…Further studies support this claim, as young males treated with risperidone reported diminished sexual function in comparison to those not treated with antipsychotics . Haloperidol shows similar effects to risperidone, as one study reported a high of 77 ng/mL in a study population .…”

Section: Discussionmentioning

confidence: 88%